The following 4 penny stocks were within the top 10 in volume traded OTC stocks on January 6, 2011 which allowed for a true opportunity for a trader to buy/sell. The other 6 stocks in the top 10 would not be viable options for penny stock traders to involve themselves with.
POWRtec International Corp. (OTCBB: POWT.OB)
POWT traded 65,490,016 shares to close Friday’s trading session down 67.20% at 0.062.
POWT has a Market Cap of 6.24M.
POWRtec International Corp. develops, produces, and sells intelligent electrical meters. The company offers meters, which are network-enabled and can be built to utilize virtually any communications protocol. This empowers the intelligent smart meters to directly control network enabled, power-draining devices by switching them on and off in accordance with the desired energy output for efficient use of resources, smaller energy bills, and benefits to the environment. It offers its products to utility companies, governments, and businesses worldwide.
Aqualiv Technologies, Inc. (OTCBB: AQLV.OB)
AQLV traded 39,334,640 shares to close Friday’s trading session up 20.00% at 0.0132.
AQLV has a Market Cap of 3.66M.
AquaLiv Technologies, Inc., through its subsidiaries, provides solutions and applications for various industries and emerging technologies. It engages in creating novel products for various industries. The company’s products include personal use products comprising AquaLiv Water Systems, AquaLiv Water Sticks, Infotone Face Mist, View All Water Systems, and Hydrogen Water Sticks; AgSmart bioinformative agriculture solutions; and industrial solutions. It also offers desktop virtualization and VoIP information technology services; and cloud computing services. The company was formerly known as Infrared Systems International and changed its name to AquaLiv Technologies, Inc. in September 2011.
Cannabis Science, Inc. (OTCBB: CBIS.OB)
CBIS traded 20,324,948 shares to close Friday’s trading session up 36.72% at 0.0175.
CBIS has a Market Cap of 4.23M.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
CBIS works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Cannabis Science sales for 2012 are forecasted to be $6,846,000 and has the potential to increase to $65,740,000 in 2014. This sales forecast translates into positive earnings of $.02 per share earnings for 2014.
Advanced Cell Technology, Inc. (OTCBB: ACTC.OB)
ACTC traded 17,107,152 shares to close Friday’s trading session up 9.59% at 0.12.
ACTC has a Market Cap of 202.40M.
Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Its embryonic stem cell research programs include cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company’s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies.
Advanced Cell Technology, Inc. also generates stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company’s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases.
About AimHighProfits.com
AimHighProfits.com strives to provide you with the hottest stock alerts in the market in Real-Time. We focus on stocks that trade for $5 per share or less, some as little as a few pennies with upside potential. Our goal is committed to producing and publishing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions and to inform you of the best stocks in the market before they move. Our focus is primarily on OTC stocks in the stock market today which have traditionally been ignored by Wall Street.
We have particular expertise with internet stocks, gold stocks, renewable energy stocks, biotech stocks, oil stocks and green energy stocks. There are many hot penny stock opportunities present in the OTC market every day and we seek to exploit these hot stock gains for our members before the average daytrader is made aware of them.
Aim High Profits Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. AimHighProfits.com is a wholly-owned subsidiary of Kelevra Media Innovation.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
ShareJAN
